The IL‐6 signaling complex is a critical driver, negative prognostic factor, and therapeutic target in diffuse large B‐cell lymphoma

The IL‐6 signaling complex is a critical driver, negative prognostic factor, and therapeutic target in diffuse large B‐cell lymphoma

Abstract Interleukin‐6 (IL‐6) is a growth factor for normal B cells and plasma cell‐derived malignancies. Here, we show that the IL‐6 signaling pathway is also active in a subset of diffuse large B‐cell lymphoma (DLBCL) patients with particularly poor prognosis. Primary DLBCL cells and DLBCL cell li...

Full description

Bibliographic Details
Main Authors: Hind Hashwah, Katrin Bertram, Kristin Stirm, Anna Stelling, Cheuk‐Ting Wu, Sabrina Kasser, Markus G Manz, Alexandre P Theocharides, Alexandar Tzankov, Anne Müller
Format: Article
Language:English
Published: Wiley 2019-10-01
Series:EMBO Molecular Medicine
Subjects:
cancer immunotherapy
DLBCL mouse models
lymphoma microenvironment
oncogenic STAT3 signaling
personalized treatment
Online Access:https://doi.org/10.15252/emmm.201910576

Internet

https://doi.org/10.15252/emmm.201910576

Similar Items